T cells and T cell tumors efficiently generate antigen-specific cytotoxic T cell immunity when modified with an NKT ligand

OncoImmunology

Volumn 1, Issue 2, 2012, Pages 141-151

  Chung, Yeonseok ^a,c   Lee, Young Hee ^a   Zhang, Yongliang ^a   Martin Orozco, Natalia ^a   Yamazaki, Tomohide ^a   Zhou, Dapeng ^a   Kang, Chang Yuil ^b   Hwu, Patrick ^a   Kwak, Larry W ^a   Dong, Chen ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Seoul National University   (South Korea)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cd1d; Cellular vaccine; Cytotoxic T cell; Inkt cell; Tumor immunity; galactosylceramide

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CASPASE 3; CD1D ANTIGEN; CD3 ANTIGEN; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 4; T CELL VACCINE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; IMMUNOPROPHYLAXIS; IN VITRO STUDY; IN VIVO STUDY; INVARIANT NATURAL KILLER T CELL; LISTERIOSIS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MELANOMA; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; T CELL DEPLETION; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION; TUMOR CELL DESTRUCTION;

EID: 84884687918     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.1.2.18479     Document Type: Article

References (33)

1. Tupin E, Kinjo Y, Kronenberg M. The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol 2007; 5:405-17; http://dx.doi.org/10.1038/nrmicro1657
2. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003; 198: 267-79; http://dx.doi.org/10.1084/jem.20030324
3. Chung Y, Chang WS, Kim S, Kang CY. NKT cell ligand alpha-galactosylceramide blocks the induction of oral tolerance by triggering dendritic cell maturation. Eur J Immunol 2004; 34:2471-9; http://dx.doi.org/10.1002/eji.200425027
4. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 2004; 199:1607-18; 15197224; http://dx.doi.org/10.1084/jem.20040317
5. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 2005; 201:1503-17; http://dx.doi.org/10.1084/jem. 20042592
6. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 2002; 3:867-74; http://dx.doi.org/10.1038/ni827
7. Lanier LL. NK cell receptors. Annu Rev Immunol 1998; 16:359-93; http://dx.doi.org/10.1146/annurev.immunol.16.1.359
8. Bendelac A. Positive selection of mouse NK1+ T cells by CD1-expressing cortical thymocytes. J Exp Med 1995; 182:2091-6; http://dx.doi.org/10.1084/jem.182.6.2091
9. Gapin L, Matsuda JL, Surh CD, Kronenberg M. NKT cells derive from double-positive thymocytes that are positively selected by CD1d. Nat Immunol 2001; 2: 971-8; http://dx.doi.org/10.1038/ni710
10. Bezbradica JS, Stanic AK, Matsuki N, Bour-Jordan H, Bluestone JA, Thomas JW, et al. Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J Immunol 2005; 174:4696-705
11. Chung Y, Kim BS, Kim YJ, Ko HJ, Ko SY, Kim DH, et al. CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo. Cancer Res 2006; 66:6843-50; http://dx.doi.org/10.1158/0008-5472.CAN-06-0889
12. Chung Y, Qin H, Kang CY, Kim S, Kwak LW, Dong C. An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. Blood 2007; 110:2013-9; http://dx.doi.org/10.1182/blood-2006-12-061309
13. Shimizu K, Goto A, Fukui M, Taniguchi M, Fujii S. Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J Immunol 2007; 178: 2853-61
14. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; http://dx.doi.org/10.1038/nri2506
15. Norbury CC, Basta S, Donohue KB, Tscharke DC, Princiotta MF, Berglund P, et al. CD8+ T cell crosspriming via transfer of proteasome substrates. Science 2004; 304:1318-21; http://dx.doi.org/10.1126/science.1096378
16. Ueda N, Kuki H, Kamimura D, Sawa S, Seino K, Tashiro T, et al. CD1d-restricted NKT cell activation enhanced homeostatic proliferation of CD8+ T cells in a manner dependent on IL-4. Int Immunol 2006; 18:1397-404; http://dx.doi.org/10.1093/intimm/dxl073
17. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, et al. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 1999; 189:1121-8; 10190903; http://dx.doi.org/10.1084/jem.189.7.1121
18. Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K, et al. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood 2002; 100: 1728-33
19. Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med 2005; 201:1973-85; 15967825; http://dx.doi.org/10.1084/jem.20042280
20. Coquet JM, Kyparissoudis K, Pellicci DG, Besra G, Berzins SP, Smyth MJ, et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 2007; 178:2827-34
21. Hayakawa Y, Takeda K, Yagita H, Van Kaer L, Saiki I, Okumura K. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J Immunol 2001; 166:6012-8
22. Ikarashi Y, Mikami R, Bendelac A, Terme M, Chaput N, Terada M, et al. Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: critical role for B7 in CD1d-dependent NKT cell interferon gamma production. J Exp Med 2001; 194:1179-86; http://dx.doi.org/10.1084/jem.194.8.1179
23. Kaneda H, Takeda K, Ota T, Kaduka Y, Akiba H, Ikarashi Y, et al. ICOS costimulates invariant NKT cell activation. Biochem Biophys Res Commun 2005; 327: 201-7; http://dx.doi.org/10.1016/j.bbrc.2004.12.004
24. Cross AH, Lyons JA, San M, Keeling RM, Ku G, Racke MK. T cells are the main cell type expressing B7-1 and B7-2 in the central nervous system during acute, relapsing and chronic experimental autoimmune encephalomyelitis. Eur J Immunol 1999; 29:3140-7; http://dx.doi.org/10.1002/(SICI) 1521-4141(199910)29:10,3140::AID-IMMU3140.3.0.CO;2-W
25. Taylor PA, Lees CJ, Fournier S, Allison JP, Sharpe AH, Blazar BR. B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions. [corrections]. J Immunol 2004; 172:34-9
26. Nurieva R, Thomas S, Nguyen T, Martin-Orozco N, Wang Y, Kaja MK, et al. T-cell tolerance or function is determined by combinatorial costimulatory signals. EMBO J 2006; 25:2623-33; http:// dx.doi.org/10.1038/sj.emboj.7601146
27. Martin-Orozco N, Wang YH, Yagita H, Dong C. Cutting Edge: Programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens. J Immunol 2006; 177:8291-5.
28. Exley M, Garcia J, Wilson SB, Spada F, Gerdes D, Tahir SM, et al. CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology 2000; 100:37-47; http://dx.doi.org/10.1046/j.1365-2567.2000.00001.x
29. Nebozhyn M, Loboda A, Kari L, Rook AH, Vonderheid EC, Lessin S, et al. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood 2006; 107:3189-96; http://dx.doi.org/10.1182/blood-2005-07-2813
30. Nurieva RI, Mai XM, Forbush K, Bevan MJ, Dong C. B7h is required for T cell activation, differentiation, and effector function. Proc Natl Acad Sci USA 2003; 100: 14163-8; http://dx.doi.org/10.1073/pnas.2335041100
31. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007; 448:480-3; http://dx.doi.org/10.1038/nature05969
32. He L, Hakimi J, Salha D, Miron I, Dunn P, Radvanyi L. A sensitive flow cytometry-based cytotoxic T-lymphocyte assay through detection of cleaved caspase 3 in target cells. J Immunol Methods 2005; 304:43-59; http://dx.doi.org/10.1016/j.jim.2005.06.005
33. Coles RM, Mueller SN, Heath WR, Carbone FR, Brooks AG. Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1. J Immunol 2002; 168: 834-8